Amarantus BioSciences in aller Munde

Wird hier gerade hoch disktutiert. Leider gibt es bei der Aktie direkt keinen Thread. Daher mach ich eben mal einen auf.

Über Amarantus: http://www.amarantus.com/

http://investorshub.advfn.com/Amarantus-BioSciences-Inc-AMBS-21711/

 

http://www.hotstocked.com/article/40292/...nc-otc-ambs-pump-goes.html

Interessanter Abschnitt: Yesterday OTC biotech company Amarantus Biosciences, Inc. (OTC:AMBS, AMBS message board) almost doubled in value, driven by pump emails and hype. The stock gained 94% and reached $0.054 at the closing bell.

The company nearly repeated its previous run of over 46 million shares traded as enthusiastic traders bought the stock on the promise pumpers and press releases touted. The story around AMBS so far is a very large cloud of optimism that contains a lot of uncertain promises for the future and not much else.

The company is being continuously pumped through email campaigns. The emails and hype are focused on the intentions AMBS has to 'pursue' therapeutic indications that 'could' lead to FDA designation of their protein as a rare-disease drug. The problem is, AMBS are nowhere near this stage in their product development. A recently published independent study reported, among other things, that the next stage of the drug testing and development is moving on to 'primate model' testing. That may give eager investors some idea how close the ultimate goal is.

 

Wahnsinnsvolumen in den USA nachdem vor fast nichts gehandelt wurde.  

 

Gestern OTC Biotech-Unternehmen Amarantus Biosciences, Inc. (OTC: AMBS, AMBS message board) fast verdoppelt im Wert, angetrieben durch eine Pumpe E-Mails und Hype. Die Aktie hat 94% und erreichte 0,054 $ bei der Abschlussveranstaltung Glocke.
Das Unternehmen nahezu wiederholt seine früheren Lauf von über 46 Millionen Aktien gehandelt als begeisterte Händler kauften die Aktie an den Versprechen Pumper und Pressemitteilungen angepriesen. Die Geschichte um AMBS so weit ist eine sehr große Wolke des Optimismus, die eine Menge von unsicheren Versprechen für die Zukunft und nicht viel mehr enthält.




Das Unternehmen wird kontinuierlich durch E-Mail-Kampagnen gepumpt. Die E-Mails und Hype auf die Absichten AMBS muss 'verfolgen' therapeutischen Indikationen, dass die FDA Ernennung ihrer Proteins könnte "führen als seltene Krankheit Medikament konzentriert. Das Problem ist, AMBS sind bei weitem nicht diesem Zeitpunkt in der Produktentwicklung. Eine kürzlich veröffentlichte unabhängige Studie berichtet, unter anderem, dass die nächste Stufe des Drogentests und Entwicklung bewegt auf 'Primatenmodell' testing. Das mag geben gerne Investoren eine gewisse Vorstellung, wie nah das ultimative Ziel ist.

Es ist mehr das ist nicht ganz richtig mit AMBS, wie ihre neuesten Quartalsbericht zeigt folgendes:
• $ 6.000 Barvermögen
• $ 4.400.000 Kurzfristige Verbindlichkeiten
• Null Umsatz im Jahr 2012
• $ 2.300.000 Nettoverlust für die ersten sechs Monaten des Jahres 2012

Mit so wenig Geld auf der Hand, es ist schwer, sich vorzustellen, wie das Unternehmen zu entwickeln und zu testen, ihre Protein effektiv beabsichtigt.

Noch schlimmer zu machen, ist CashMoneyPlay einer der Pumper wirbt AMBS. Mit dem im Verstand, können Händler in der Lage sein, einige Rückschlüsse auf die Entwicklung der vergangenen Beständen der gleichen pumpers gefördert stützen. Ein solches Beispiel ist IJJP, ein Unternehmen, das an der absoluten unten $ 0,0001, nachdem er von CashMoneyPlay März gepumpt Flatlined.

Anleger sollten bedenken, dass OTC-Aktien besonders hohen Risiko ausgesetzt sind. Gepumpt und gefördert OTC-Aktien sind noch schlimmer Kandidat für Ihre Investition als Kursbewegung künstlich durch pumper Kampagnen gefahren. Denken Sie daran, Ihre eigene Due Diligence tun und kein Vertrauen in die Hype von Pumper erstellt

 

Lohnt es sich hier einzusteigen oder eher heiss?

 

hab mal 50k gekauft. in us 35% short. da sollte was gehen heute und den rest der woche

 

Ziel bis Christmas 0,5-1$ ;)

BERLIN RT 0,07 +68%

 

http://ih.advfn.com/...bol=AMBS&period=0&size=19&volume=1

 

aber in die falsche Richtung?!

 

0.059

-0.0064

-9.79

21,954,211

11/13/12 3:41:12

0.066

0.0689

0.052

Aber in die falsche Richtung. Da ich hier nicht drin bin, kann man mal überlegen....

 

Sagt mal, werden hier massig Aktien auf den Markt geschmissen? Das Ganze hat doch System? Ich bin da echt skeptisch....

 

eine rakete schüttelt sich immer vorm start. richtig gute news und aussichten. sollten heute weitere news kommen könnte es heftig werden. shortrate bei 40% und die decken bekanntlich mittwochs!

aufpassen heute!

 

Hat jemand einen Link für mich?

Welche News sind hier zu erwarten?

 

nachgeschossen. supernews gestern kurz vor handelsschluss. da sollte aus den panikverkäufern von gestern wohl heute panikkäufer werden ;). aber ist ja immer so alle verkaufen und es steigt

 

zu Ø 0,024. das ding wir die nächsten wochen sehr hoch fliegen. am wochenende steht auch ein termin zur präsentation in us an. die firma hat ein blockbustermedikament welches vielen leuten helfen könnte, schon alleine das ist mir mein geld wert.

es werden hier noch weitere große investoren kommen, wenn nicht vorher ein buyout stattfindet.

 

in us gestern auf th und +20% geschlossen! das sollte heute den shortkessel zum kochen bringen. denn hier sind noch einige naked ;)

 

gutes volumen in berlin (700k/tag) und us (10-20mio/tag), also auch immer flüssig die kleine

 

bitte DIESEN newsflow und den inhalt dieser doch vielen Meldungen beachten. eine der aktien die man wohl so schnell nicht wieder findet. m.M.n riesen chance hier.

http://www.finanznachrichten.de/...tien/amarantus-biosciences-inc.htm

Und hier RT US für 15.30

http://ih.advfn.com/...bol=AMBS&period=0&size=19&volume=1

 

AMBS is clearly setting itself up for a partnership with a larger pharma company. Remember what Rubinfeld said:
"I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

The most recent advisors added to the board are:
*Dr Joseph Rubinfeld - co-founder of Amgen
*Clinton Allen - Bristol Myers Squibb, Director of Product Development and Commercialization, Director of In-licensing and Business Development
*Dr. Robert Zimmerman - Vice President of Biotechnology Research at Bayer Corporation

Keep in mind what Mr. Zimmerman said:
"I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."

They stated in their press release that "Dr. Zimmerman will also assist in the procurement of relationships with top-tier vendors".

Additionally, they are pursuing an Orphan Drug strategy with MANF which many investors seem to have forgotten about.

And don't forget their patents on MANF which don't expire until 2031:
“Today’s announcement is transformational for Amarantus from a scientific data standpoint,” said Gerald E. Commissiong, President & CEO of Amarantus. “Despite the many clear scientific
advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson’s disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson’s patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today’s data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway.”"

 

20% unter pari schmeißen?

bei den aussichten und vor us eröffnung???

also manche müssen ihr geld doch selber drucken!

 

Danke!

 

herzlichen glückwunsch dem käufer zu diesem kurs weit unter pari. ich hab es leider verschlafen ;(

die hätte ich auch genommen

 

hat man in berlin aktien verkauft die man hätte nicht verkaufen dürfen? kennt jemand ähnliche fälle? muss der berliner mm nun alle aktien teuer zurückkaufen? man kann doch an einer börse nicht einfach was verkaufen wozu man nicht berechtigt ist? bin ratlos...

wäre dankbar über hilfe

 

die berliner shares könnten dann noch einen geldsegen für die besitzer bringen.

 

Das sollte den Kurs doch wieder in Fahrt bringen!

http://ih.advfn.com/...nmona&article=55195222&symbol=…

 

 

 

Amarantus BioSciences Announces Positive Data for MANF in Delivery  Diffusion Animal Model of Parkinson's Disease

Print

Amarantus Biosci (OTCBB:AMBS) Intraday Stock Chart Today : Tuesday 27 November 2012   SUNNYVALE, Calif., Nov. 27, 2012 /PRNewswire/ -- Amarantus BioSciences,  Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying  treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury  centered on its proprietary anti-apoptosis therapeutic protein MANF, today  announced that the Company has successfully completed experiments demonstrating  that MANF has an excellent diffusion profile in the striatum of rat brains. The  striatum is located in the brain, and is partially responsible for proper  movement as part of the basal ganglia network. The striatum becomes severely  compromised in Parkinson's disease due to neurite retraction from dopaminergic  neurons located in the substantia nigra. The data generated in this study show  that when compared to GDNF, a neurotrophic factor currently in a Phase 2  clinical trial for Parkinson's disease, MANF had a significantly higher volume  of distribution when delivered to the striatum. These results are part of  on-going animal studies to determine the best localization of delivering MANF to  the brain in Parkinson's disease human clinical studies. "The data obtained in this study provide  strong evidence that volume distribution from the site of delivery in the brain  is unlikely to be an impediment to MANF's clinical progress," said John W. Commissiong,  PhD, Chief Scientist at Amarantus. "Volume distribution from the site of  delivery appears to have been one of the key shortfalls of previous clinical  trials of neurotrophic factors in Parkinson's disease.  These results provide a  higher degree of certainty that MANF is unlikely to fail in the clinic due to  inadequate diffusion volumes." In studies conducted by Dr. Steven Gill's  laboratory at the University of Bristol, MANF and GDNF were injected directly  into the striatum of separate groups of rats in order to mimic as closely as  possible the treatment setting in humans. Seven days following delivery under  best available conditions, MANF's diffusion volume was ~30% greater than GDNF's. "The results of this study provide further  support to MANF's real-world potential as a disease-modifying treatment for  Parkinson's disease, and potentially other brain disorders," said Gerald E. Commissiong,  President and CEO of Amarantus. "Diffusion from the site of delivery in the  brain has been a key problem plaguing the development of other neurotrophic  factors for Parkinson's disease for some time. We now have further evidence that  MANF appears to have added biological advantages over other neurotrophic factors  in development, and the Company intends to leverage these results as we continue  to advance our Parkinson's program, as well as explore additional applications  for MANF in orphan disease applications. The Company is currently evaluating  various delivery technologies to clinically deliver MANF to the brain in  Parkinson's disease, and will update the market of its intentions as definitive  agreements emerge." Large  pharmaceutical companies have shown significant interest in neurotrophic factors  for Parkinson's disease for over two decades. In 1993, Amgen acquired Synergen for $262  million shortly after Synergen successfully completed studies using GDNF as  a protein therapeutic in animal models of Parkinson's disease. In 2007, Genzyme entered into a $150 million  partnership with Ceregene to gain access to ex-U.S. marketing rights  Neurturin after Ceregene successfully completed a Phase 1 clinical study  demonstrating safety for Neurturin as a gene therapy product. Amarantus owns  composition of matter and method of use patents for MANF, including claims for  use of MANF as a protein therapy, gene therapy and as an adjuvant within the  context of cell therapy. About  Amarantus BioSciences, Inc. Amarantus  BioSciences, Inc. is a development-stage biotechnology company founded in  January 2008.  The Company has a focus on developing certain biologics  surrounding the intellectual property and proprietary technologies it owns to  treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other  human diseases.  The Company owns the intellectual property rights to a  therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor  ("MANF") and is developing MANF-based products as treatments for brain  disorders. The Company also is a Founding Member of the Coalition for Concussion  Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports  International seeking to raise awareness of new treatments in development for  concussions and nervous-system disorders. For further information please visit  www.Amarantus.com. Forward  Looking Statements   This press release contains forward-looking  statements within the meaning of the Private Securities Litigation Reform Act of  1995. Such statements include, but are not limited to, statements about the  possible benefits of MANF therapeutic applications and/or advantages presented  by Amarantus' PhenoGuard technology, as well as statements about expectations,  plans and prospects of the development of Amarantus' new product candidates.  These forward-looking statements are subject to a number of risks, uncertainties  and assumptions, including the risks that the anticipated benefits of the  therapeutic drug candidates or discovery platforms, as well as the risks,  uncertainties and assumptions relating to the development of Amarantus' new  product candidates, including those identified under "Risk Factors" in  Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report  on Form 10-Q and in other filings Amarantus periodically makes with the SEC.  Actual results may differ materially from those contemplated by these  forward-looking statements Amarantus does not undertake to update any of these  forward-looking statements to reflect a change in its views or events or  circumstances that occur after the date of this presentation.